Form 4: Altimmune Director Catherine Sohn Granted 48,800 Options

Altimmune, Inc. director Catherine A. Sohn received 48,800 stock options as part of the company's standard non-employee director compensation policy.

Summary

• Director Catherine A. Sohn was granted 48,800 stock options on May 1, 2026.
• The options carry an exercise price of 2.82 per share.
• The grant was issued under the company's non-employee director compensation policy.
• Vesting occurs in substantially equal monthly installments over the 12 months following the grant date.
• The options have a ten-year term, expiring on May 1, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing consistent with standard corporate governance and director remuneration.

Positives

• Aligns director interests with shareholder value through equity-based compensation.
• Vesting schedule encourages long-term commitment and service to the board.
• Exercise price of 2.82 sets a clear benchmark for future stock price appreciation goals.

Negatives

• Represents potential future dilution of 48,800 shares for existing shareholders.
• The low exercise price of 2.82 may reflect a period of lower market valuation for the company.

Risks

• The options only provide value if the market price of the stock exceeds the 2.82 exercise price.
• Vesting is contingent upon the reporting person's continued service through each applicable date.

Future Outlook

The grant indicates a continued strategy of using equity to attract and retain board-level talent while preserving cash for clinical development.

Management Comments

• The options were granted pursuant to the Company's non-employee director compensation policy.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is standard in the biotech industry to align board oversight with the high-risk, high-reward nature of drug development.

Comparison to Industry Standards

• The 12-month monthly vesting schedule is a common benchmark for director grants in the biotech sector, similar to practices at Viking Therapeutics.
• A 10-year option term is the standard duration for incentive and non-qualified stock options in U.S. public companies.

Corporate Governance

Related Party Transactions

• Issuance of stock options to Director Catherine A. Sohn as part of her standard compensation package.

Stakeholder Impact

• Shareholders face minor potential dilution upon the eventual exercise of these options.
• The director is incentivized to oversee strategies that drive the stock price above 2.82.

Next Steps

• Options will vest in monthly increments through May 2027.
• The director may exercise vested options at any time prior to the 2036 expiration date.

Key Dates

Recommendation

This filing is a routine compensation event and does not provide new material information regarding the company's clinical trials or financial runway that would alter a fundamental investment thesis.

Keywords

Altimmune, ALT, Insider Trading, Form 4, Stock Options, Director Compensation, Biotechnology, Catherine Sohn